Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. (PubMed, N Engl J Med) - Oct 1, 2026 - P3 | "In adults with obesity, retatrutide resulted in significant weight reduction, reduced pain in participants with knee osteoarthritis, and reduced apnea-hypopnea events in participants with obstructive sleep apnea. (Funded by Eli Lilly; TRIUMPH-1 ClinicalTrials.gov number, NCT05929066.)."
Clinical • Journal • Diabetes • Genetic Disorders • Immunology • Metabolic Disorders • Obesity • Obstructive Sleep Apnea • Osteoarthritis • Pain • Respiratory Diseases • Rheumatology • Sleep Disorder
|
|
; Ania M Jastreboff; John P H Wilding; Kathryn Giblin; Lee M Kaplan; Megan Murray; Melanie J Davies; Nadia N Ahmad; Nanette C Schloot; Nune Makarova; Yan Wang; Yu Du
|